210 related articles for article (PubMed ID: 10779025)
1. Survey ranking of emetogenic control in children receiving chemotherapy.
Small BE; Holdsworth MT; Raisch DW; Winter SS
J Pediatr Hematol Oncol; 2000; 22(2):125-32. PubMed ID: 10779025
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Holdsworth MT; Raisch DW; Winter SS; Chavez CM
Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
[TBL] [Abstract][Full Text] [Related]
3. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies.
Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K
J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
6. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.
Inui N
Med Oncol; 2017 May; 34(5):77. PubMed ID: 28365889
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
[TBL] [Abstract][Full Text] [Related]
9. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
11. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Holdsworth MT; Raisch DW; Duncan MH; Chavez CM; Leasure MM
Ann Pharmacother; 1995 Jan; 29(1):16-21. PubMed ID: 7711340
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
13. Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide.
Meden H; Meissner O; Conrad A; Kuhn W
Eur J Gynaecol Oncol; 1996; 17(2):114-22. PubMed ID: 8654467
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
15. FLOT (a chemotherapy regimen for gastric/esophagogastric junction cancer): to be treated as a highly emetogenic regimen or a moderately emetogenic one? Comparison of the emetogenic potential of FLOT versus FOLFOX and TAC regimens.
Ghorbani M; Dehghani M; Fahimfar N; Namazi S; Dehshahri A
Support Care Cancer; 2022 May; 30(5):3865-3873. PubMed ID: 35038031
[TBL] [Abstract][Full Text] [Related]
16. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
17. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
18. Computerized system for outcomes-based antiemetic therapy in children.
Holdsworth MT; Adams VR; Raisch DW; Wood JG; Winter SS
Ann Pharmacother; 2000 Oct; 34(10):1101-8. PubMed ID: 11054974
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Handberg J; Kjaer M; Dombernowsky P
J Clin Oncol; 2001 Apr; 19(7):2091-7. PubMed ID: 11283143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
